Publication: Understanding the Mechanism of Action of Melatonin, Which Induces ROS Production in Cancer Cells.
dc.contributor.author | Florido, Javier | |
dc.contributor.author | Rodriguez-Santana, Cesar | |
dc.contributor.author | Martinez-Ruiz, Laura | |
dc.contributor.author | Lopez-Rodriguez, Alba | |
dc.contributor.author | Acuña-Castroviejo, Dario | |
dc.contributor.author | Rusanova, Iryna | |
dc.contributor.author | Escames, Germaine | |
dc.contributor.funder | Consejería de Innovación, Ciencia y Empresa, Junta de Andalucía | |
dc.contributor.funder | University of Granada Spain | |
dc.contributor.funder | Ministerio de Educación Cultura y Deporte, Spain. | |
dc.contributor.funder | ERDF | |
dc.date.accessioned | 2023-05-03T13:47:04Z | |
dc.date.available | 2023-05-03T13:47:04Z | |
dc.date.issued | 2022-08-19 | |
dc.description.abstract | Reactive oxygen species (ROS) constitute a group of highly reactive molecules that have evolved as regulators of important signaling pathways. In this context, tumor cells have an altered redox balance compared to normal cells, which can be targeted as an antitumoral therapy by ROS levels and by decreasing the capacity of the antioxidant system, leading to programmed cell death. Melatonin is of particular importance in the development of innovative cancer treatments due to its oncostatic impact and lack of adverse effects. Despite being widely recognized as a pro-oxidant molecule in tumor cells, the mechanism of action of melatonin remains unclear, which has hindered its use in clinical treatments. The current review aims to describe and clarify the proposed mechanism of action of melatonin inducing ROS production in cancer cells in order to propose future anti-neoplastic clinical applications. | |
dc.description.version | Si | |
dc.identifier.citation | Florido J, Rodriguez-Santana C, Martinez-Ruiz L, López-Rodríguez A, Acuña-Castroviejo D, Rusanova I, e al. Understanding the Mechanism of Action of Melatonin, Which Induces ROS Production in Cancer Cells. Antioxidants (Basel). 2022 Aug 20;11(8):1621. | |
dc.identifier.doi | 10.3390/antiox11081621 | |
dc.identifier.issn | 2076-3921 | |
dc.identifier.pmc | PMC9404709 | |
dc.identifier.pmid | 36009340 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404709/pdf | |
dc.identifier.unpaywallURL | https://www.mdpi.com/2076-3921/11/8/1621/pdf?version=1661425530 | |
dc.identifier.uri | http://hdl.handle.net/10668/20789 | |
dc.issue.number | 8 | |
dc.journal.title | Antioxidants (Basel, Switzerland) | |
dc.journal.titleabbreviation | Antioxidants (Basel) | |
dc.language.iso | en | |
dc.organization | Hospital Universitario San Cecilio | |
dc.organization | Hospital Universitario San Cecilio | |
dc.organization | Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA) | |
dc.page.number | 13 | |
dc.provenance | Realizada la curación de contenido 13/08/2024 | |
dc.publisher | MDPI AG | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Review | |
dc.relation.projectID | MCIN/AEI/10.13039/501100011033 | |
dc.relation.projectID | SAF2017-85903-P | |
dc.relation.projectID | ID2020-115112RB-I00 | |
dc.relation.projectID | P07-CTS-03135 | |
dc.relation.projectID | P10-CTS-5784 | |
dc.relation.projectID | CTS-101 | |
dc.relation.projectID | “UNETE” | |
dc.relation.projectID | UCE-PP2017-05 | |
dc.relation.publisherversion | https://www.mdpi.com/resolver?pii=antiox11081621 | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | apoptosis | |
dc.subject | cancer | |
dc.subject | melatonin | |
dc.subject | mitochondria | |
dc.subject | reactive oxygen species | |
dc.subject.decs | Antioxidantes | |
dc.subject.decs | Apoptosis | |
dc.subject.decs | Efectos colaterales y reacciones adversas relacionados con medicamentos | |
dc.subject.decs | Enfermedad iatrogénica | |
dc.subject.decs | Especies reactivas de oxígeno melatonina | |
dc.subject.decs | Oxidación-reducción | |
dc.subject.decs | Transducción de señal | |
dc.subject.mesh | Antioxidants | |
dc.subject.mesh | Melatonin | |
dc.subject.mesh | Reactive Oxygen Species | |
dc.subject.mesh | Drug-Related Side Effects and Adverse Reactions | |
dc.subject.mesh | Iatrogenic Disease | |
dc.subject.mesh | Signal Transduction | |
dc.subject.mesh | Apoptosis | |
dc.subject.mesh | Oxidation-Reduction | |
dc.title | Understanding the Mechanism of Action of Melatonin, Which Induces ROS Production in Cancer Cells. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 11 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1